HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA guidance

This article was originally published in The Tan Sheet

Executive Summary

"Submission of Abbreviated Reports and Synopses in Support of Marketing Applications" guidance, expected to appear in the Sept. 13 Federal Register, describes when studies that are part of an NDA may be submitted to FDA in abbreviated form and describes the format abbreviated submissions should follow. The agency estimates the resulting reduction in burden for industry will be 300 hours. A draft of the guidance appeared in the Sept. 21 Federal Register (1"The Tan Sheet" Sept. 28, 1998, p. 24). Comments may be submitted at any time

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS140397

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel